RenovoRx, Inc. (RNXT)

1.56 -0.10 (-6.02%) USD  |  NASDAQ  |  Sep 28, 15:52
More

RenovoRx Cash from Operations (Annual) : -10.97M for Dec. 31, 2025

Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for RNXT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2019. Start Trial.
Date Value
December 31, 2025 -10.97M
December 31, 2024 -9.125M
December 31, 2023 -10.26M
December 31, 2022 -8.811M
Date Value
December 31, 2021 -5.916M
December 31, 2020 -3.528M
December 31, 2019 -3.35M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Enanta Pharmaceuticals, Inc. -19.27M
Travere Therapeutics, Inc. 37.78M
REGENXBIO, Inc. -123.96M
Krystal Biotech, Inc. 200.86M
ACADIA Pharmaceuticals, Inc. 109.84M